Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Pfister

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
JAMA Oncology|October 26, 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical TrialStéphane Oudard, Raffaele Ratta, Eric Voog, et al.
European Urology Oncology|August 14, 2024
Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY TrialStephane Oudard, Yohann Tran, Carole Helissey, et al.
NPJ Precision Oncology|June 17, 2021
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapyMartin Thelen, Kerstin Wennhold, Jonas Lehmann, et al.
The Journal of Urology|May 20, 2020
Reply by AuthorsNicola Fossati, Simone Scarcella, Giorgio Gandaglia, et al.
The Journal of Urology|February 19, 2020
Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of <sup>68</sup>Ga-PSMA and <sup>11</sup>C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node DissectionsNicola Fossati, Simone Scarcella, Giorgio Gandaglia, et al.
BJUI Compass|December 26, 2022
Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancerCarlo A Bravi, Axel Heidenreich, Nicola Fossati, et al.
European Urology|July 7, 2020
Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional SeriesCarlo A Bravi, Nicola Fossati, Giorgio Gandaglia, et al.
European Urology Focus|August 19, 2025
Oncologic Outcomes of Template Versus Radioguided Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography Scan: Results from a Multi-institutional CollaborationCarlo Andrea Bravi, Sophie Knipper, Axel Heidenreich, et al.
European Urology|July 7, 2020
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously ThoughtCarlo A Bravi, Nicola Fossati, Giorgio Gandaglia, et al.
European Urology Oncology|June 28, 2021
Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal TherapyCarlo A Bravi, Matteo Droghetti, Nicola Fossati, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
JAMA Oncology|October 26, 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical TrialStéphane Oudard, Raffaele Ratta, Eric Voog, et al.
European Urology Oncology|August 14, 2024
Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY TrialStephane Oudard, Yohann Tran, Carole Helissey, et al.
NPJ Precision Oncology|June 17, 2021
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapyMartin Thelen, Kerstin Wennhold, Jonas Lehmann, et al.
The Journal of Urology|May 20, 2020
Reply by AuthorsNicola Fossati, Simone Scarcella, Giorgio Gandaglia, et al.
The Journal of Urology|February 19, 2020
Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of <sup>68</sup>Ga-PSMA and <sup>11</sup>C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node DissectionsNicola Fossati, Simone Scarcella, Giorgio Gandaglia, et al.
BJUI Compass|December 26, 2022
Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancerCarlo A Bravi, Axel Heidenreich, Nicola Fossati, et al.
European Urology|July 7, 2020
Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional SeriesCarlo A Bravi, Nicola Fossati, Giorgio Gandaglia, et al.
European Urology Focus|August 19, 2025
Oncologic Outcomes of Template Versus Radioguided Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography Scan: Results from a Multi-institutional CollaborationCarlo Andrea Bravi, Sophie Knipper, Axel Heidenreich, et al.
European Urology|July 7, 2020
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously ThoughtCarlo A Bravi, Nicola Fossati, Giorgio Gandaglia, et al.
European Urology Oncology|June 28, 2021
Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal TherapyCarlo A Bravi, Matteo Droghetti, Nicola Fossati, et al.
Pageof 20